Comparative Pharmacology
Head-to-head clinical analysis: ASPIRIN OMEPRAZOLE versus PREVACID NAPRAPAC 375 COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPIRIN OMEPRAZOLE versus PREVACID NAPRAPAC 375 COPACKAGED.
ASPIRIN; OMEPRAZOLE vs PREVACID NAPRAPAC 375 (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aspirin irreversibly acetylates cyclooxygenase (COX-1 and COX-2), inhibiting thromboxane A2 synthesis and platelet aggregation. Omeprazole is a proton pump inhibitor that irreversibly binds to H+/K+-ATPase in gastric parietal cells, reducing gastric acid secretion.
Lansoprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the gastric H+/K+-ATPase at the secretory surface of the gastric parietal cell. Naproxen, a nonsteroidal anti-inflammatory drug, inhibits cyclooxygenase (COX-1 and COX-2) reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Aspirin 81 mg orally once daily plus omeprazole 20 mg orally once daily.
One tablet (naproxen 375 mg / lansoprazole 15 mg) orally twice daily.
None Documented
None Documented
Aspirin: 15-20 minutes for parent drug; salicylate half-life 2-3 hours at low doses, increasing to >20 hours at high doses due to saturable hepatic metabolism; clinically, dosing interval adjusted for antiplatelet effect (low dose) vs anti-inflammatory (high dose). Omeprazole: 0.5-1 hour; no accumulation on repeated dosing; metabolized via CYP2C19 and CYP3A4.
Naproxen: 12-17 hours (mean 14 hours); allows twice-daily dosing. Lansoprazole: 1.5-2 hours (fast metabolizers) to 3-4 hours (slow metabolizers); clinically negligible due to irreversibly binding to proton pumps.
Aspirin: renal elimination of salicylate and its metabolites (salicyluric acid, salicyl phenolic glucuronide, salicyl acyl glucuronide, gentisic acid); ~10% excreted unchanged in urine; dose-dependent due to saturable metabolism. Omeprazole: ~80% eliminated as metabolites in urine, ~20% in feces via biliary excretion.
Naproxen: Approximately 95% excreted in urine as unchanged naproxen (10%) and metabolites (~60% 6-O-desmethylnaproxen and conjugates); <5% in feces. Lansoprazole: Primarily metabolized in liver; metabolites excreted in urine (14-23%) and feces (~22%).
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor/NSAID Combination